Latest news and press releases about Evolus, Inc. (EOLS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc.
Price
| Price | $7.99 |
| Market Cap | $526M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -17.05 |
| EV / EBITDA | -62.16 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 123.11% |
| Return on Invested Capital | -15.27% |
| Return on Assets | -13.84% |
| Gross Margin | 66.25% |
| Operating Margin | -7.33% |
| Net Margin | -10.85% |
Related companies: AUTL · CBLL · EHAB · KIDS · KMDA · NGNE · QSI
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of EOLS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks